SCHEMBL17491553

SCHEMBL17491553

O=S(=O)(Nc1cc2c(c(-c3cnco3)c1)OCC2)C1CC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SGK1 O00141 1/20 0.33
▸ CYP17A1 P05093 2/20 0.32
▸ AAK1 Q2M2I8 3/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ PSEN1 P49768 1/20 0.32
▸ PSEN2 P49810 1/20 0.32
▸ APH1B Q8WW43 1/20 0.32
▸ NCSTN Q92542 1/20 0.32
▸ APH1A Q96BI3 1/20 0.32
▸ PSENEN Q9NZ42 1/20 0.32
▸ PRMT6 Q96LA8 5/20 0.32
▸ POLB P06746 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ PTGS2 P35354 1/20 0.31
▸ PRMT1 Q99873 1/20 0.31
▸ PRMT8 Q9NR22 1/20 0.31
▸ MAP2K7 O14733 1/20 0.30
▸ MAP2K4 P45985 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17491433 0.79 CYP3A4 (0.47) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL17506994 0.78 IMPDH2 (0.37) PDE4B
SCHEMBL17491487 0.78 DYRK1A (0.44) AAK1CYP3A4WNT1GSK3BDYRK1A
SCHEMBL17491414 0.72 BRPF1 (0.35) SGK1CYP17A1AAK1MAP2K7MAP2K4
SCHEMBL17491545 0.72 GAA (0.39) AAK1KMT2A
SCHEMBL17491493 0.72 IMPDH2 (0.40) DYRK1A
SCHEMBL17491388 0.71 RHOA (0.41) SGK1CYP17A1CYP3A4CYP2D6PSEN1
SCHEMBL17491492 0.70 ROCK2 (0.46) KMT2A
SCHEMBL17491406 0.68 MAOA (0.40) CYP3A4KMT2APDE4B
SCHEMBL17491444 0.62 IMPDH2 (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982670-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-11-07 — — EP disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-20160052897-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-25 — — US disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052897-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 SGK1 4443/4885CYP17A1 267/4885AAK1 4342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback